Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroendocrine Tumors × Tamoxifen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 245 Carcinoma, Intraductal, Noninfiltrating 21 Breast Carcinoma In Situ 17 Neoplasm Metastasis 14 Neoplasms 12 Breast Neoplasms, Male 11 Ovarian Neoplasms 8 Inflammatory Breast Neoplasms 6 Glioblastoma 5 Endometrial Neoplasms 5 Central Nervous System Neoplasms 4 Breast Cancer Female 4 Recurrence 3 Prostatic Neoplasms 3 Obesity 3 Gliosarcoma 3 Fallopian Tube Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Carcinoma, Ductal, Breast 3 Brain Neoplasms 3 Urinary Bladder Neoplasms 2 Sleep Wake Disorders 2 Pancreatic Neoplasms 2 Multiple Endocrine Neoplasia Type 1 2 Hot Flashes 2 Glioma 2 Fibroadenoma 2 ER+ Breast Cancer 2 Carcinoma, Lobular 2 Astrocytoma 2

Interventions

lutetium Lu 177 dotatate 39 Everolimus 31 Magnetic Resonance Spectroscopy 15 lanreotide 13 gallium Ga 68 dotatate 12 Octreotide 12 Temozolomide 11 Capecitabine 11 Nivolumab 10 177Lu-octreotide, DOTA(0)-Tyr(3)- 10 surufatinib 9 pembrolizumab 8 cabozantinib 8 Positron Emission Tomography Computed Tomography 8 3-Iodobenzylguanidine 8 Sunitinib 7 Specimen Handling 7 amino-acid, glucose, and electrolyte solution 6 Somatostatin 6 Lutetium-177 6 90Y-octreotide, DOTA-Tyr(3)- 6 telotristat ethyl 5 pasireotide 5 Ga(III)-DOTATOC 5 Fluorodeoxyglucose F18 5 Carboplatin 5 Bevacizumab 5 olaparib 4 copper dotatate CU-64 4 avelumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03870399 2024-05-06

HORMONET

AC Camargo Cancer Center

Phase 2 Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡